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specific gene expression in colorectal cancer cells
Darina L Lazarova, Christopher Chiaro and Michael Bordonaro*Abstract
Background: We have determined that butyrate, which is derived from the fermentation of dietary fiber in the
colonic lumen, hyperactivates Wnt activity in colorectal (CRC) cells, and that this upregulation of Wnt signaling is
causatively related to the induction of apoptosis. To better understand the genetic program regulated by
butyrate-mediated Wnt hyperactivation, we performed total human genome microarray analyses on HCT-116 CRC
cells in the presence or absence of a physiologically relevant concentration of butyrate. To evaluate changes in
Wnt-specific gene expression, Wnt activity was suppressed with inducible dominant negative Tcf4 (DN-Tcf4). Six
biological replicates of a full human genome microarray were performed, and the data deposited into the Gene
Expression Omnibus database, according to Minimum Information About A Microarray Experiment standards.
Results: Reporter assay and western blot data confirm that DN-Tcf4 is expressed at high levels in stably transfected
HCT-116 cells upon cotreatment with doxycycline and butyrate, and that these cells exhibit a marked repression of
butyrate-mediated Wnt hyperactivation. Analysis of six biological replicates of microarray analyses indicated that
1008 genes are modulated by butyrate (>two-fold, P < 0.01) in a Wnt signaling-specific manner, while 1587 genes
are similarly modulated at P < 0.05. The modulated genes include members of a variety of gene families; including
the Biological Process category, such as regulation of development, regulation of metabolism, cytokine and
chemokine mediated signaling pathways, and DNA replication; the Cellular Component category such as
cytoskeleton and organelle factors, and intermediate filaments; and the Molecular Function category, such as
GTPase activator activity.
Conclusions: We have identified, for the first time, in CRC cells, the total array of direct and indirect Wnt-target
genes whose expression is modulated by butyrate. Knowledge of the molecular mechanisms determining the
response of CRC cells to butyrate in vitro may assist in determining more effective preventive and therapeutic
strategies against CRC.
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Canonical Wnt signaling is induced by the binding of
Wnt ligands to cell surface receptors, resulting in the
inactivation of intact Axin 1-containing complexes [1],
and accumulation of transcriptionally active beta-catenin
[1-5] which interacts with Tcf DNA binding proteins
[6-11]. Beta-catenin-Tcf transcriptional complexes drive
transcription from Tcf site-containing promoters, in-
cluding both reporter constructs and endogenous Wnt
responsive genes containing Tcf/Lef sites [8,9] and refs.
therein. Constitutively active Wnt signaling, caused by* Correspondence: mbordonaro@tcmedc.org
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unless otherwise stated.mutations in the APC and beta-catenin genes [8-10]
promotes colonic cell proliferation and tumorigen-
esis; however, both relatively high and relatively low
levels of Wnt transcriptional activity lead to CRC cell
apoptosis [12-16].
Colorectal cancer (CRC) may to some extent be
preventable through diet [13,14,17-22]. The protective
action of dietary fiber against CRC has been attributed
to its fermentation in the colon, producing the histone
deacetylase inhibitor (HDACi) butyrate [23,24]. HDA-
Cis induce cell cycle arrest, differentiation, and/or apop-
tosis of CRC cells [25,26]; the HDACis butyrate and
trichostatin A (TSA), which induce apoptosis in CRC
cells in vitro, hyperactivate Wnt transcriptional activityal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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HDACis, to promote CRC apoptosis and repress cell
growth, is casually related to the degree of Wnt hyper-
activation induced by these agents [12-14].
To determine the genetic program regulated by butyrate-
mediated Wnt hyperactivation, we performed total human
microarray analysis on HCT-116 CRC cells. Cells were
treated with a physiologically relevant concentration
(5 mM) of butyrate [24] or left untreated. To evaluate
changes in Wnt-specific gene expression, Wnt activity was
suppressed with inducible dominant negative Tcf4 (DN-
Tcf4), which competes with endogenous beta-catenin-Tcf
(BCT) complexes for binding to promoter sequences of
Wnt target genes [8]. We identified more than one
thousand genes that exhibited Wnt-specific changes in
expression (>two-fold, P < 0.01) after exposure to butyr-
ate. These changes in gene expression include a variety
of gene families, representing clusters of functionally
related gene products.
Thus, in this short Research Article/Data Note, we iden-
tify, for the first time, in a human CRC cell line, how
exposure to butyrate modulates the expression of genes
that are direct or indirect targets of Wnt signaling.Methods
Plasmids, cell lines, transfection, luciferase assay
pTOPFLASH (TOP), pFOPFLASH (FOP), and inducible
DN-Tcf4 were from Dr. H. Clevers (UMC Utrecht, Utrecht,
Netherlands). Tet repressor plasmid was from Invitrogen
(Carlsbad, CA). HCT-116 cells were obtained from the
American Type Culture Collection (ATCC). Transfection
with lipofectamine 2000 and luciferase assays were per-
formed as previously described [12-14]. Measurements
of Wnt transcriptional activity were performed with the
TOP/FOP luciferase reporter system that has wild-type
(TOP) or mutant (FOP) Tcf binding sites upstream of a
minimal c-fos promoter (8, 9).Nucleofection and stable transfection
Standard protocol was utilized according to manufacturer’s
instructions. Setting D-32 was used to nucleofect HCT-116
cells. Routinely, 2 μg of DNA and 1 × 106 cells were used
per well (6 well plate) for each nucleofection. HCT-116
cells were stably transfected, via nucleofection, with a vec-
tor for Tet repressor and a Tet-inducible DN-Tcf4 vector
[27,28]. Cells were selected with 100 μg/ml zeocin and
5 μg/ml blasticidin, and DN-Tcf4 expression was induced
by doxycycline (4 μg/ml), followed by clonal selection.
Clones were assayed based on doxycycline-inducible sup-
pression of Wnt activity as measured by reporter assays,
and expression of DN-Tcf4 as evaluated by western blot
analysis.Genus biosystems total human genome microarray
analysis
After treatment with or without 4 μg/ml doxycycline
and then cotreatment with or without 5 mM sodium bu-
tyrate (NaB) for 17.5 hr, cells were washed with 1 × PBS,
scraped into PBS and pelleted; the pellets were snap
frozen in liquid nitrogen and sent to Genus Biosystems
(Northbrook, IL) for RNA extraction and microarray
analyses, utilizing the Agilent human whole genome oligo
microarray. Briefly, RNA extraction and array analyses
were performed by Genus as follows. RNA was extracted
and purified with Ambion Ribopure isolation, with RNA
quality assessed by an Agilent Bioanalyzer. Following first
and second strand cDNA synthesis, cRNA target was
prepared, fragmented to a uniform size, and hybridized
to Agilent Human v2 GE 4x44K arrays. Slides were
subsequently washed and scanned on an Agilent G2565
Microarray Analyzer and the resulting data were ana-
lyzed with Agilent Feature Extraction and GeneSpring
GX v7.3.1 software. A total of six biological replicates of
the experiment were performed.
Western blotting
Anti-FLAG antibody (Origene, Rockville, MD) was used
to detect the FLAG-tagged DN-Tcf4. Actin was used a
loading control using anti-actin antibody (Sigma, St. Louis,
MO). Protein isolation and western blotting were
performed as previously described [12-14].
Statistics
For gene transfection experiments, Students t-test was
utilized, with statistical significance set at P < 0.05 for
the Wnt reporter experiments. For microarray analyses,
paired T-test was used at P < 0.01 and P < 0.05.
Results and discussion
Characterization of system
We have established that physiologically relevant con-
centrations of butyrate induce apoptosis, and repress
clonal growth, in CRC cells dependent upon the hyper-
activation of Wnt activity [12-14]. Therefore, it is likely
that a set of Wnt signaling targeted genes mediates the
high apoptotic response of CRC cells to butyrate. To bet-
ter evaluate differences in gene expression that contribute
to the butyrate response, we determined the pattern of
gene expression changes due to butyrate treatment, focus-
ing on genes which are direct or indirect Wnt targets. We
identified these genes by microarray analyses of HCT-116
cells, in which Wnt signaling is suppressed. Thus, we
established a stably transfected HCT-116 cell line express-
ing doxycycline-inducible DN-Tcf4. DN-Tcf4 is a form of
Tcf4 that lacks the beta-catenin interaction domain and
represses Wnt activity by competing with BCT complexes
for access to DNA binding sites in Wnt target genes (8).
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presses the upregulation of Wnt activity by butyrate in a
variety of CRC cell lines, including HCT-116 ([12-14]
and data not shown).
In the stably transfected cell clone, induction with
doxycycline repressed the ability of butyrate to upregulate
Wnt activity, as expected (Figure 1A, B). Wnt activity was
measured by luciferase reporter assays, comparing the ex-
pression from a Wnt-sensitive reporter (pTOPFLASH) to
that of the control reporter that is not responsive to Wnt
signaling (pFOPFLASH) ([12-14] and refs. therein). Un-
treated cells exhibited a TOP/FOP ratio, indicative of Wnt
activity, of 5.5 which was increased to 106.0 (P < 0.002)
by treatment with 5 mM butyrate. Treatment with













































Figure 1 Clone 19 exhibits doxycycline-induced downregulation
of the Wnt hyperactivation by butyrate. (A) Cells were transfected
with TOPFlash or FOPFlash reporters and pRLTK (to control for
transfection efficiency) and expression of DN-Tcf4 was induced by
treatment with 4 μg/ml doxycycline; cells were also treated or not
treated with 5 mM butyrate (NaB), both agents (DoxyNaB); control
(Ctl) cells were not treated with either agent. After 17 hr of butyrate
treatment, Wnt transcriptional activity was measured via luciferase
assays. T/F represents the ratio of expression of TOPFlash (wild-type
Wnt-responsive promoter) compared to FOPFlash (mutant
promoter), measuring overall canonical Wnt activity. (B) Data from
(A) represented by the fold-upregulation of Wnt activity in the
presence (DoxyNaB/Doxy) or absence (NaB/Ctl) of doxycycline.
(A) and (B) show data from four independent experiments. Bars,
SDs. * = statistical significance.which was increased to 4.7 with combinatorial treat-
ment with both doxycycline and butyrate (P < 0.05).
Thus, the fold-upregulation of Wnt activity by butyrate
in the presence of doxycycline was approximately 10-fold
lower (P < 0.001) than in the absence of doxycycline.
Consistent with our previous findings with stable
transfection of inducible DN-Tcf4 in DLD-1 CRC cells,
and transient transfection of this vector in HCT-116
cells [13], basal expression of stably transfected DN-
Tcf4 is minimal in the presence of doxycycline and
absence of butyrate, but is at high levels in the presence
of both agents (Figure 2). The likely reason for low basal
levels of DN-Tcf4 in the absence of butyrate is counter-
selection during clonal selection; clones that would express
high levels of DN-Tcf4 in the presence of doxycycline
and absence of butyrate would also likely express lower,
but physiologically relevant, levels of DN-Tcf4 in the
absence of doxycycline. This background expression
would likely inhibit cell growth during clonal expansion
compared to clones exhibiting lower DN-Tcf4 expres-
sion. Given the ability of butyrate to upregulate induced
DN-Tcf4 expression in these cells, the relative repres-
sion of DN-Tcf4 expression in the absence of butyrate
may involve (a) histone deacetylation of the DN-Tcf4
promoter sequences, which is reversed by the HDACi
activity of butyrate; and/or (b) repressed expression of
activating transcription factors or enhanced expression
of transcriptional repressors, both targeting the DN-Tcf4
promoter. In the latter case, butyrate would be expected to
favor DN-Tcf4 transcriptional activation through altered
expression of these transcriptional factors.
Given that combinatorial treatment of cells with doxy-
cycline and butyrate results in high expression of the Wnt
inhibitor DN-Tcf4 (Figure 2), why does the combination
of these two agents result in an increase in the TOP/FOP
ratio compared to doxycycline alone (Figure 1A)? Butyrate
increases the TOP/FOP ratio in CRC cells through the
marked hyperactivation of Wnt signaling [12-14]. In the
absence of DN-Tcf4 expression, the TOP/FOP ratio is
increased from 5.5 to 106 by butyrate treatment (NaB vs.
Ctl in Figure 1A). This extremely large activation of Wnt
activity is not completely eliminated by the presence ofDN-Tcf4
Actin
Ctl              NaB           Doxy           Both
Figure 2 Overexpression of DN-Tcf4 in induced HCT-116 cells.
A stably transfected clone of HCT-116 cells was treated with 4 μg/ml
doxycycline (Doxy) and/or 5 mM NaB for 17.5 hr or left untreated.
Protein was isolated, and DN-Tcf4 detected with anti-FLAG antibody
in western blot analysis. Actin was analyzed as a control. Duplicate
samples from a representative western blot shown.
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FOP ratio, from 2.5 to 4.7, is observed upon doxycycline/
butyrate cotreatment compared to doxycycline alone
(DoxyNaB vs. Doxy in Figure 1A).
However, the main experimental comparison for our
microarray analyses was that of (a) butyrate treatment
alone compared to control (NaB/Ctl) vs. (b) doxycycline
and butyrate treatment compared to doxycycline alone
(DoxyNaB/Doxy). Thus, the small upregulation of Wnt
activity still induced by butyrate in the presence of DN-
Tcf4 expression (1.9-fold) is an order of magnitude less
(P < 0.001) than that induced by butyrate in the absence
of DN-Tcf4 (19.3-fold) (compare NaB/Ctl to DoxyNaB/
Doxy in Figure 1B). This 10-fold difference in Wnt hyper-
activation by butyrate observed +/− DN-Tcf4 allows us to
identify changes in Wnt-target gene expression induced
by butyrate.
The observed expression pattern of DN-Tcf4 (Figure 2)
is favorable, since the objective was to compare gene ex-
pression in the presence or absence of butyrate-enhanced
Wnt signaling. Thus, we aimed at repressed Wnt activity
upon butyrate treatment; this aim was achieved, as dem-
onstrated by the markedly reduced Wnt hyperactivation
shown in Figure 1.
We expected that known Wnt activity-targeted genes
would exhibit reduced gene expression in the presence
of induced DN-Tcf4, and this was confirmed. Table 1
shows the relative expression of selected Wnt/Tcf targeted
genes [27-29]; some of these genes were previously shown
to exhibit repressed expression in the presence of induced
DN-Tcf4 in LS174T and DLD-1 CRC cells [27,28]. Relative
expression levels are shown, after induction with doxycyc-
line alone (Doxy) compared to untreated control (Ctl), orTable 1 Relative expression of Wnt/Tcf-targeted genes
upon doxycycline induction in the presence or absence
of butyrate
Relative expression of Wnt/Tcf-targeted genes












Numbers in italics represent differences that are statistically significant at
P < 0.01.after induction and butyrate treatment (Doxy +NaB) com-
pared to butyrate treatment alone (NaB). Induction with
doxycycline alone resulted in moderate to no change in
the expression of these genes, while the combination of
doxycycline induction and butyrate treatment resulted in
statistically significant downregulation. Therefore, as ex-
pected, expression of Wnt activity-targeted genes is down-
regulated upon the high induction of DN-Tcf4 observed
after treatment of cells with doxycycline and butyrate.
Experimental approach
The experimental approach was to use human whole
genome microarray analyses to first identify all genes
whose expression was up- or downregulated by butyrate,
in a statistically significant manner, by > two-fold, in the
absence of induced DN-Tcf4. We then repeated the ana-
lysis in the presence of doxycycline/butyrate-induced
DN-Tcf4, and considered those genes whose expression
was modulated by butyrate in the absence of doxycycline
(intact Wnt signaling) but not similarly modulated in
the presence of doxycycline (repressed Wnt signaling).
Thus, we were interested in identifying those genes that
are differentially expressed (>two-fold, P < 0.01) in the
NaB vs. Ctrl comparison but not differentially expressed
(>two-fold, P < 0.01) in the Doxy + NaB vs. Doxy com-
parison. The NaB vs. Ctrl comparison yields all genes
differentially expressed after exposure to 5 mM butyrate,
while the Doxy + NaB vs. Doxy comparison yields all
butyrate-modulated genes except those that are Wnt
activity-targeted, since doxycycline induction combined
with butyrate treatment efficiently induces DN-Tcf4
expression (Figure 2). Additional information about the
experimental design, samples, and raw data are included
in Additional files 1 and 2.
Identification of genes, the expression of which is
modulated by butyrate-mediated Wnt signaling
Microarray analyses identified a number of genes whose
expression levels are modified by butyrate in a manner
sensitive to repression of Wnt activity by DN-Tcf4 [30].
Thus, a total of 1008 genes were identified which were
modulated by butyrate alone (up- or downregulation) by
at least 2-fold with P < 0.01, and 1587 genes at P < 0.05,
but were not similarly modulated by butyrate when Wnt
activity was repressed (induction of DN-Tcf4 by doxycyc-
line and butyrate) (Figure 3).
Gene ontology analysis of the microarray data reveals
a number of functionally relevant gene families, ex-
pression of which is influenced by butyrate in a Wnt
signaling-dependent manner (Table 2). These gene fam-
ilies include the (a) Biological Process category, such as
regulation of development, regulation of metabolism,
cytokine and chemokine mediated signaling pathways,
and DNA replication; (b) Cellular Component category
Figure 3 Differential expression of genes in NaB vs. Control NOT Doxy + NaB vs. Doxy. (A) Condition tree. Genes are displayed as normalized to
the median expression across 4 samples within each experiment (>two-fold, paired T-test, P < 0.01, 1008 probes). Red/Orange = Up-regulated
relative to median, Yellow = Median expression, Blue = Dn-regulated relative to median. (B) Venn diagram emphasizes comparison of NaB vs.
Ctrl or Doxy + NaB vs. Doxy (>two-fold, paired T-test, P < 0.01).
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mediate filaments; and (c) Molecular Function category,
such as GTPase activator activity.
Our results are most consistent with the modulation
of multiple physiological and cell signaling pathways by
butyrate-hyperinduced Wnt activity in CRC cells. These
data can be utilized to identify relevant gene targets
whose expression can be up- or down-regulated as part
of preventive and/or therapeutic approaches against
CRC. Further, the array findings can be utilized to better
understand the mechanisms behind the physiological ef-
fects of butyrate on neoplastic colonic cells, particularly
those effects dependent upon modulation of Wnt signal-
ing. In addition, an understanding of Wnt-dependent
butyrate-mediated changes in gene expression can in-
form about the development of butyrate resistance inCRC, which we have shown involves repressed induction
of Wnt signaling in the presence of butyrate [14]. There-
fore, future studies will be aimed at (a) up- or down-
regulating relevant genes in vitro using overexpression
or knockdown strategies, to ascertain effects on cell
physiology, including, but not limited to, cell growth,
differentiation, and apoptosis, as well as response to bu-
tyrate and other HDACis; and (b) in vivo targeted gene
overexpression or knockout in murine models of CRC,
to evaluate effects on intestinal morphology, tumor for-
mation, and response to dietary or therapeutic interven-
tions, utilizing fiber/butyrate or other HDACis that
mimic the effects of butyrate in cell culture [14]. These
additional findings can also contribute to the development
of more efficacious anti-CRC preventive/therapeutic
methodologies.
Table 2 Microarray data gene ontology classifications
Gene ontology
Microarray data gene ontology classifications
Category = the name of the category
within the ontology.
Genes in category = the total number of
genes in the genome that have been
assigned to the category
Genes in list in category = the total
number of genes both in the selected






GO:50769: positive regulation of
neurogenesis
101 14
GO:51094: positive regulation of
development
420 30
GO:50793: regulation of development 848 49
GO:45598: regulation of fat cell
differentiation
59 9
GO:50772: positive regulation of
axonogenesis
47 8
GO:1779: natural killer cell differentiation 4 3
GO:9991: response to extracellular
stimulus
238 19
GO:50767: regulation of neurogenesis 280 21
GO:45600: positive regulation of fat cell
differentiation
20 5
GO:45444: fat cell differentiation 126 12
GO:30844: positive regulation of
intermediate filament depolymerization
2 2













GO:48541: Peyer’s patch development 7 3
GO:50789: regulation of biological process 8048 292
GO:31667: response to nutrient levels 211 16




GO:9892: negative regulation of
metabolism
1238 58
GO:45595: regulation of cell differentiation 612 33
GO:51093: negative regulation of
development
292 19
GO:6066: alcohol metabolism 576 31
1126 52
Table 2 Microarray data gene ontology classifications
(Continued)
GO:31324: negative regulation of cellular
metabolism
GO:31668: cellular response to
extracellular stimulus
64 7
GO:30901: midbrain development 34 5
GO:48715: negative regulation of
oligodendrocyte differentiation
11 3
GO:9912: auditory receptor cell fate
commitment
4 2
GO:31670: cellular response to nutrient 4 2
GO:19221: cytokine and chemokine
mediated signaling pathway
249 16
GO:42423: catecholamine biosynthesis 24 4
GO:1709: cell fate determination 38 5
GO:6260: DNA replication 343 20
GO:8089: anterograde axon cargo
transport
13 3
GO:50768: negative regulation of
neurogenesis
89 8
GO:30879: mammary gland development 39 5
GO:45773: positive regulation of axon
extension
25 4
GO:45686: negative regulation of glial cell
differentiation
25 4
GO:17085: response to insecticide 25 4
GO:50770: regulation of axonogenesis 91 8
GO:15879: carnitine transport 14 3
GO:19800: peptide cross-linking via
chondroitin 4-sulfate glycosaminoglycan
5 2






GO:5622: intracellular 16495 558
GO:43229: intracellular organelle 13641 467
GO:43226: organelle 13647 467







GO:796: condensin complex 9 3
GO:5856: cytoskeleton 2219 92
GO:15630: microtubule cytoskeleton 1021 48
GO:5813: centrosome 467 26




GO:43227: membrane-bound organelle 12386 415
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Table 2 Microarray data gene ontology classifications
(Continued)





















GO:8307: structural constituent of muscle 70 7
GO:8047: enzyme activator activity 573 30
GO:19894: kinesin binding 25 4
GO:31730: CCR5 chemokine receptor
binding
5 2
GO:17123: Ral GTPase activator activity 5 2
Clusters of genes whose expression is modulated as described in Figure 3 and
Table 1, grouped into functionally relevant categories.
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In summary, this study is the first examination of the
total set of direct and indirect Wnt-target genes whose
expression is modulated by butyrate in a human CRC
cell line. These data suggest a large number of potential
gene targets for anti-CRC therapeutic intervention, par-
ticularly for those approaches involving fiber/butyrate/
HDACis. Knowledge of the molecular mechanisms de-
termining the response of CRC cells to butyrate in vitro
may assist in determining more effective preventive and
therapeutic strategies against CRC.Availability of supporting data
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